Systematic Inflammatory Profiling Reveals Immune Modulation in Response to Weight Loss Intervention

Sapient leveraged our DynamiQ™ biorepository to build a virtual cohort for the study, encompassing individuals with at least one blood sample collected prior to and following GLP-1 treatment and with associated pre- and post-therapy weight measurements. These samples were first analyzed using the NULISAseq Inflammation Panel 250, which provides ultra-high sensitivity to profile biomarkers of inflammation and immune response in the low-abundance proteome to the attomolar level.

You’ll see that this case study exemplifies the importance of assaying a broad spectrum of inflammatory markers –beyond those that are already well known – to gain a more complete understanding of immune modulation in response to GLP-1 treatment. What we found was that while commonly measured biomarkers such as C-reactive protein (CRP), tumor necrosis factor (TNF), and interferons (IFN) are not among those changed with GLP-1 therapy, a number of other biologically relevant inflammatory markers did show significant changes pre- and post-GLP-1 treatment.

You’ll also see how integrating the NULISAseq findings with other multi-omics data, specifically discovery proteomics and metabolomics, allowed us to begin to elucidate the molecular mechanisms of immune response to GLP-1 therapy mediated by those key inflammatory markers. Through the analysis, we found links between the markers and pathways involved in energy expenditure, oxidative phosphorylation, mitochondrial biogenesis, and regulation of insulin sensitivity.

Complete the form to read the full case study!